Table 3 Medical history of participants at enrolment into the CoLTART study by sex and site
Medical condition | All combined | Entebbe site | Kyamulibwa site | ||||
|---|---|---|---|---|---|---|---|
n (%) | All, n (%) | Sex | All, n (%) | Sex | |||
Females, n (%) | Males, n (%) | Females, n (%) | Males, n (%) | ||||
All | 1095 | 666 | 459 (68.9) | 207 (31.1) | 429 | 252 (58.7) | 177 (41.3) |
Hypertension history | |||||||
 Never had hypertension | 936 (85.5) | 556 (83.5) | 378 (82.4) | 178 (86.0) | 380 (88.6) | 222 (88.1) | 158 (89.3) |
 Ever had hypertension | 159 (14.5) | 110 (16.5) | 81 (17.6) | 29 (14.0) | 49 (11.4) | 30 (11.9) | 19 (10.7) |
Diabetes mellitus historya | |||||||
 No known diabetes mellitus | 1067 (97.9) | 645 (97.3) | 445 (97.4) | 200 (97.1) | 422 (98.8) | 248 (98.8) | 174 (98.9) |
 Known diabetes mellitus | 23 (2.1) | 18 (2.7) | 12 (2.6) | 6 (2.9) | 5 (1.2) | 3 (1.2) | 2 (1.1) |
Renal disease historyb | |||||||
 No renal disease | 1087 (99.4) | 659 (99.1) | 456 (99.3) | 203 (98.5) | 428 (99.8) | 252 (100.0) | 176 (99.4) |
 Known renal disease | 7 (0.6) | 6 (0.9) | 3 (0.7) | 3 (1.5) | 1 (0.2) | 0 (0.0) | 1 (0.6) |
ART exposure, years | |||||||
 ART naïve | 74 (6.8) | 27 (4.1) | 21 (4.6) | 6 (2.9) | 47 (11.0) | 22 (8.7) | 25 (14.1) |
 <1 years | 79 (7.2) | 13 (2.0) | 11 (2.4) | 2 (1.0) | 66 (15.4) | 35 (13.9) | 31 (17.5) |
 1 to <5 years | 164 (15.0) | 7 (1.1) | 6 (1.3) | 1 (0.5) | 157 (36.6) | 98 (38.9) | 59 (33.3) |
 5 to <9 years | 124 (11.3) | 15 (2.3) | 9 (2.0) | 6 (2.9) | 109 (25.4) | 65 (25.8) | 44 (24.9) |
 9+ years | 654 (59.7) | 604 (90.7) | 412 (89.8) | 192 (92.8) | 50 (11.7) | 32 (12.7) | 18 (10.2) |
Metabolic abnormalities study groupsc | |||||||
 Non-protease Inhibitor based ART | 785 (76.9) | 432 (67.6) | 306 (69.9) | 126 (62.7) | 353 (92.4) | 212 (92.2) | 141 (92.8) |
 Protease Inhibitor based ART | 236 (23.1) | 207 (32.4) | 132 (30.1) | 75 (37.3) | 29 (7.6) | 18 (7.8) | 11 (7.2) |
Renal dysfunction study groupsd | |||||||
 Tenofovir containing ART | 608 (59.6) | 500 (78.3) | 337 (76.9) | 163 (81.1) | 108 (28.3) | 64 (27.8) | 44 (29.0) |
 Non-Tenofovir containing ART | 413 (40.5) | 139 (21.8) | 101 (23.1) | 38 (18.9) | 274 (71.7) | 166 (72.2) | 108 (71.1) |
Body mass index (kg/m2)e | |||||||
 <18.5 | 114 (10.6) | 48 (7.4) | 29 (6.5) | 19 (9.4) | 66 (15.4) | 29 (11.5) | 37 (21.0) |
 18.5–24.9 | 674 (62.8) | 365 (56.6) | 217 (49.0) | 148 (73.3) | 309 (72.2) | 175 (69.4) | 134 (76.1) |
 25.0–29.9 | 218 (20.3) | 172 (26.7) | 140 (31.6) | 32 (15.8) | 46 (10.8) | 41 (16.3) | 5 (2.8) |
 ≥30 | 67 (6.3) | 60 (9.3) | 57 (12.9) | 3 (1.5) | 7 (1.6) | 7 (2.8) | 0 (0.0) |
Haemoglobin (g/dl)f | |||||||
 Normal | 908 (83.3) | 570 (86.2) | 387 (85.1) | 183 (88.8) | 338 (78.8) | 199 (79.0) | 139 (78.5) |
 Abnormal | 182 (16.7) | 91 (13.8) | 68 (14.9) | 23 (11.2) | 91 (21.2) | 53 (21.0) | 38 (21.5) |
CD4 cell counts at enrolment (cells/µl)g | |||||||
 ≤350 | 307 (30.1) | 182 (30.6) | 102 (25.2) | 80 (42.3) | 125 (29.3) | 65 (26.1) | 60 (33.9) |
 351–500 | 327 (32.1) | 171 (28.8) | 118 (29.1) | 53 (28.0) | 156 (36.6) | 89 (35.7) | 67 (37.9) |
 501+ | 386 (37.8) | 241 (40.6) | 185 (45.7) | 56 (29.6) | 145 (34.0) | 95 (38.2) | 50 (28.2) |
Viral loads at enrolment (cells/ml)h | |||||||
 ≤1000 copies/ml | 823 (77.7) | 528 (81.6) | 363 (81.2) | 165 (82.5) | 295 (71.6) | 180 (75.3) | 115 (66.5) |
 >1000 copies/ml | 236 (22.3) | 119 (18.4) | 84 (18.8) | 35 (17.5) | 117 (28.4) | 59 (24.7) | 58 (33.5) |